Agenus Inc

AGENNASDAQ · USD
6.14USD0.00 (-4.07%)
5210

Agenus Inc (AGEN) Historical Volatility

AGEN's 30 day historical volatility is 77.25%, in the 25th percentile of readings over the past year. This is a low percentile, meaning Agenus Inc shares have been calmer than usual. AGEN's 30 day implied volatility sits at 84.70%, with an IV Rank of 2.38%, leaving IV 7.45 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 19, 2026.

Read more

Tracking AGEN historical volatility helps you see how much Agenus Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AGEN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AGEN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AGEN's 30 day historical volatility, or AGEN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AGEN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.

Historical Volatility

HV Percentile
25thHV Percentile
Low

Historical movement is subdued versus the past year. The stock has been unusually quiet.

Historical Volatility (30d)77.25%

HV Percentile25th

Implied Volatility (30d)84.70%

IV Rank2.38%

IV Minus HV+7.45%

As of Nov 19, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 19, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →